AU2016288188B2 - Ketamine transdermal delivery system - Google Patents

Ketamine transdermal delivery system Download PDF

Info

Publication number
AU2016288188B2
AU2016288188B2 AU2016288188A AU2016288188A AU2016288188B2 AU 2016288188 B2 AU2016288188 B2 AU 2016288188B2 AU 2016288188 A AU2016288188 A AU 2016288188A AU 2016288188 A AU2016288188 A AU 2016288188A AU 2016288188 B2 AU2016288188 B2 AU 2016288188B2
Authority
AU
Australia
Prior art keywords
transdermal delivery
delivery device
ketamine
hours
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016288188A
Other languages
English (en)
Other versions
AU2016288188A1 (en
Inventor
Michael MAYERSOHN
Hock S. Tan
Huadong Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenox Pharmaceuticals LLC
Original Assignee
Shenox Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenox Pharmaceuticals LLC filed Critical Shenox Pharmaceuticals LLC
Publication of AU2016288188A1 publication Critical patent/AU2016288188A1/en
Application granted granted Critical
Publication of AU2016288188B2 publication Critical patent/AU2016288188B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016288188A 2015-06-27 2016-06-27 Ketamine transdermal delivery system Ceased AU2016288188B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562185573P 2015-06-27 2015-06-27
US62/185,573 2015-06-27
PCT/US2016/039601 WO2017003935A1 (en) 2015-06-27 2016-06-27 Ketamine transdermal delivery system

Publications (2)

Publication Number Publication Date
AU2016288188A1 AU2016288188A1 (en) 2018-01-04
AU2016288188B2 true AU2016288188B2 (en) 2021-08-05

Family

ID=57609546

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016288188A Ceased AU2016288188B2 (en) 2015-06-27 2016-06-27 Ketamine transdermal delivery system

Country Status (9)

Country Link
US (2) US11191734B2 (enExample)
EP (1) EP3297620A4 (enExample)
JP (1) JP6845162B2 (enExample)
KR (1) KR102299359B1 (enExample)
CN (1) CN107847469A (enExample)
AU (1) AU2016288188B2 (enExample)
CA (1) CA2987909C (enExample)
HK (1) HK1248578A1 (enExample)
WO (1) WO2017003935A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
WO2018091473A1 (en) 2016-11-15 2018-05-24 Klaria Pharma Holding Ab Pharmaceutical formulation
WO2018195318A1 (en) * 2017-04-20 2018-10-25 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine
TW201946617A (zh) * 2017-04-28 2019-12-16 日商日東電工股份有限公司 經皮吸收製劑
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
CN107823195A (zh) * 2017-11-24 2018-03-23 无锡市精神卫生中心 R‑氯胺酮在抑郁症急性期治疗中的应用
IL319020A (en) 2017-12-22 2025-04-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
MX2020011269A (es) 2018-04-25 2020-12-11 Shinkei Therapeutics Llc Dispositivo de administración transdérmica de tetrabenazina.
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
US20210308040A1 (en) * 2018-10-26 2021-10-07 Guangzhou Dazhou Biomedicine Ltd. Ketamine oral transmucosal delivery system
CN111346073B (zh) * 2018-12-21 2022-06-10 宜昌人福药业有限责任公司 一种透皮给药的药物组合物及其制备方法和应用
MA55218A (fr) 2019-03-05 2022-01-12 Janssen Pharmaceuticals Inc Eskétamine pour le traitement de la dépression
US11752114B2 (en) 2019-04-17 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
EP3725306A1 (en) 2019-04-17 2020-10-21 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system
AU2020257564B2 (en) * 2019-04-17 2023-03-02 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system
CN109966272A (zh) * 2019-04-30 2019-07-05 深圳市泛谷药业股份有限公司 一种氯胺酮透皮贴剂及其制备方法
GB201912505D0 (en) * 2019-08-30 2019-10-16 Klaria Pharma Holding Ab Pharmaceutical formulation
TWI862759B (zh) 2019-12-20 2024-11-21 昱展新藥生技股份有限公司 氯胺酮雙羥萘酸鹽的長效注射劑型
US11559497B2 (en) 2020-06-19 2023-01-24 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts
CN117797130A (zh) * 2022-09-30 2024-04-02 宜昌人福药业有限责任公司 S-氯胺酮经皮组合物及其制备方法和应用
WO2024067729A1 (zh) * 2022-09-30 2024-04-04 宜昌人福药业有限责任公司 S-氯胺酮经皮组合物及其制备方法和应用
US12005035B1 (en) * 2023-08-14 2024-06-11 Daniel C. Javitt Compositions and methods for treatment of chronic pain and depression
WO2025037252A1 (en) * 2023-08-14 2025-02-20 Javitt Daniel C Compositions and methods for treatment of chronic pain and depression

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
US20110178114A1 (en) * 2008-06-30 2011-07-21 Afgin Phara Llc Topical regional neuro-affective therapy
US20120270916A1 (en) * 2002-11-25 2012-10-25 Taraxos Inc. Topical formulations for treating neuropathy
US20140256821A1 (en) * 2006-03-22 2014-09-11 Icahn School Of Medicine At Mount Sinai Intrannasal administration of ketamine to treat depression

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635204A (en) * 1994-03-04 1997-06-03 Montefiore Medical Center Method for transdermal induction of anesthesia, analgesia or sedation
WO1997007750A1 (en) * 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
PT2266558T (pt) 2001-06-07 2017-07-21 Analgesic Neuropharmaceuticals Llc Tratamento da dor neuropática com o antagonista dos recetores de n-metil-d-aspartato (nmda) dextrometorfano
US6855735B2 (en) 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
US20050148673A1 (en) 2002-07-11 2005-07-07 Harbut Ronald E. Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004045601A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050222270A1 (en) 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
US8741332B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
EP1861104A4 (en) 2005-03-04 2011-12-14 Neurosystec Corp IMPROVED GACYCLIDINE FORMULATIONS
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CA2685344A1 (en) 2007-04-26 2008-11-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
CA2688294C (en) * 2007-06-08 2012-08-07 Dong-Won Kim Matrix-type transdermal drug delivery system and preparation method thereof
CA2738468A1 (en) 2008-09-27 2010-04-01 Taraxos Inc. Topical formulations for treatment of neuropathy
US8394759B2 (en) 2008-11-21 2013-03-12 Cymbiotics, Inc. Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes
JP2010229045A (ja) 2009-03-26 2010-10-14 Mikasa Seiyaku Co Ltd 経皮吸収型製剤
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
CN103108631B (zh) 2010-06-15 2015-08-26 格吕伦塔尔有限公司 用于治疗疼痛的联合药物
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
US9724315B2 (en) * 2011-09-30 2017-08-08 Cmpd Licensing, Llc Compounded transdermal pain management
CN104395283A (zh) 2011-10-14 2015-03-04 美国政府健康及人类服务部 (2r,6r)-羟基去甲氯胺酮、(s)-脱氢去甲氯胺酮以及(r,s)-氯胺酮的其他立体异构脱氢和羟基化代谢物在治疗忧郁症和神经性疼痛中的应用
WO2013088135A1 (en) 2011-12-14 2013-06-20 Astrazeneca Ab Gabr-a2 diagnostic
PL2809307T3 (pl) * 2012-01-31 2018-06-29 Grünenthal GmbH Plaster farmaceutyczny do podawania przezskórnego (1r,4r)-6'-fluoro-N,N-dimetylo-4-fenylo-4',9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4-b]indolo]-4-aminy
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
PE20141906A1 (es) 2012-03-12 2014-12-05 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
WO2013149102A1 (en) 2012-03-30 2013-10-03 The General Hospital Corporation Compositions comprising scopolamine and ketamine in the treatment of depression
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
KR20150096370A (ko) 2012-08-23 2015-08-24 스튜어트 엘. 웨그 항불안제 조성물, 제형 및 사용방법
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
JP6309957B2 (ja) 2012-10-08 2018-04-11 オークランド ユニサービシーズ リミティド ケタミン誘導体
US20140274981A1 (en) 2013-03-15 2014-09-18 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
EP2983787B1 (en) 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
EP3964203A1 (en) 2013-09-13 2022-03-09 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
WO2015123750A1 (en) * 2014-02-20 2015-08-27 Cura Health Inc. Transdermal composition for treating pain
US11207316B2 (en) 2014-05-30 2021-12-28 West Virginia University Ketamine or dextromethorphan formulations and methods of use
WO2016025581A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
RU2771275C2 (ru) 2014-11-04 2022-04-29 Аморса Терапьютикс, Инк. Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения
US20180015054A1 (en) 2014-12-31 2018-01-18 Icahn School Of Medicine At Mount Sinai Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
WO2016172672A1 (en) 2015-04-24 2016-10-27 Icahn School Of Medicine At Mount Sinai Method for treating suicidal ideation
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017041112A1 (en) 2015-09-04 2017-03-09 Cyprus Therapeutics, Inc. Ketamine and cytochrome p 450 inhibitor combinations
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2017139382A1 (en) 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
EP3413903A4 (en) 2016-02-12 2019-09-18 Synergistic Therapeutics, LLC ANTIDEPRESSIVE SUBLINGUAL AIRPLANE
US20170266319A1 (en) 2016-03-21 2017-09-21 Children's Hospital Medical Center Methods and compositions for treating conditions associated with spinal cord injury
AU2017238859B2 (en) 2016-03-25 2021-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine
CN109475514A (zh) 2016-03-25 2019-03-15 美国政府健康及人类服务部 使用(2r,6r)-羟基去甲氯胺酮和(2s,6s)-羟基去甲氯胺酮治疗抑郁、焦虑、快感缺乏、疲劳、自杀意念和创伤后应激障碍的方法
GB2564990A (en) 2016-04-01 2019-01-30 Good Pharmaceutical Dev Company Llc Topical compositions for neuropathic pain
AU2017250086A1 (en) 2016-04-11 2018-09-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US20170348252A1 (en) 2016-04-21 2017-12-07 Robert Kent Preparation and Use of Ketamine Derivatives and Ketamine Modifiers in the Treatment of Pain
US11213495B2 (en) 2016-05-25 2022-01-04 National Health Research Institutes Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine
EP3463323B1 (en) 2016-06-03 2021-10-20 Small Pharma Ltd Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
WO2018195318A1 (en) 2017-04-20 2018-10-25 Guangzhou Dazhou Biomedicine Ltd. Transdermal drug delivery system for ketamine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082225A1 (en) * 2001-10-19 2003-05-01 Mason Paul Arthur Sterile, breathable patch for treating wound pain
US20120270916A1 (en) * 2002-11-25 2012-10-25 Taraxos Inc. Topical formulations for treating neuropathy
US20140256821A1 (en) * 2006-03-22 2014-09-11 Icahn School Of Medicine At Mount Sinai Intrannasal administration of ketamine to treat depression
US20110178114A1 (en) * 2008-06-30 2011-07-21 Afgin Phara Llc Topical regional neuro-affective therapy

Also Published As

Publication number Publication date
KR102299359B1 (ko) 2021-09-07
JP6845162B2 (ja) 2021-03-17
AU2016288188A1 (en) 2018-01-04
US20180353437A1 (en) 2018-12-13
WO2017003935A1 (en) 2017-01-05
JP2018518498A (ja) 2018-07-12
CA2987909C (en) 2022-04-26
CN107847469A (zh) 2018-03-27
CA2987909A1 (en) 2017-01-05
US11191734B2 (en) 2021-12-07
KR20180021127A (ko) 2018-02-28
EP3297620A4 (en) 2019-01-09
US20220193000A1 (en) 2022-06-23
HK1248578A1 (zh) 2018-10-19
EP3297620A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
US20220193000A1 (en) Ketamine transdermal delivery system
US20220395469A1 (en) Transdermal drug delivery system for ketamine
RU2408368C2 (ru) Препараты соли бупропиона с модифицированным высвобождением
JP6212104B2 (ja) オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑止性経皮製剤
AU2007280470B2 (en) Granule and orally disintegrating tablet comprising oxycodone
US20210308040A1 (en) Ketamine oral transmucosal delivery system
JP5073124B2 (ja) ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤
Gupta et al. Transdermal delivery: product and patent update
RU2504363C2 (ru) Усилитель чрескожного всасывания и трансдермальный препарат с его использованием
JPWO2021202329A5 (enExample)
US20230123388A1 (en) Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
EP4192440B1 (en) Esketamine-suspension-tts
HK40025664A (en) Transdermal drug delivery system for ketamine
JP2010030909A (ja) フェンタニル類を含む経皮吸収型貼付剤およびその製造方法ならびにフェンタニル類の結晶析出抑制方法および結晶析出抑制剤
HK40086503A (en) Esketamine-suspension-tts
HK40086503B (en) Esketamine-suspension-tts
JP2021102573A (ja) クエン酸フェンタニル含有経皮吸収製剤
HK1125857B (en) Granule and orally disintegrating tablet comprising oxycodone
HK1125857A (en) Granule and orally disintegrating tablet comprising oxycodone
HK1072541A1 (zh) 治療不寧腿綜合症的經皮給藥形式

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired